Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical tria...
Main Authors: | Thai Hoa Thi Nguyen, Xuan Dung Pham, Khanh Linh Dao, Thanh Toan Vo |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-07-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/516404 |
Similar Items
-
EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
by: Xinyu von Buttlar, MD, MS, et al.
Published: (2021-06-01) -
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
by: Ryohei Katayama, et al.
Published: (2016-01-01) -
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
by: Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, et al.
Published: (2021-03-01) -
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01) -
Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01)